key: cord-0878190-o0p9wmuj
authors: Xu, Shuang-yong; Fomenkov, Alexey; Chen, Tien-Hao; Yigit, Erbay
title: Expression of human ACE2 N-terminal domain, part of the receptor for SARS-CoV-2, in fusion with maltose binding protein, E. coli ribonuclease I and human RNase A
date: 2021-02-01
journal: bioRxiv
DOI: 10.1101/2021.01.31.429007
sha: c7f2880dee6a8f4a15887fd1be07da2fc874a6d7
doc_id: 878190
cord_uid: o0p9wmuj

The SARS-CoV-2 viral genome contains a positive-strand single-stranded RNA of ~30 kb. Human ACE2 protein is the receptor for SARS-CoV-2 virus attachment and initiation of infection. We propose to use ribonucleases (RNases) as antiviral agents to destroy the viral genome in vitro. In the virions the RNA is protected by viral capsid proteins, membrane proteins and nucleocapsid proteins. To overcome this protection we set out to construct RNase fusion with human ACE2 receptor N-terminal domain (ACE2NTD). We constructed six proteins expressed in E. coli cells: 1) MBP-ACE2NTD, 2) ACE2NTD-GFP, 3) RNase I (6xHis), 4) RNase III (6xHis), 5) RNase I-ACE2NTD (6xHis), and 6) human RNase A-ACE2NTD150 (6xHis). We evaluated fusion expression in different E. coli strains, partially purified MBP-ACE2NTD protein from the soluble fraction of bacterial cell lysate, and refolded MBP-ACE2NTD protein from inclusion body. The engineered RNase I-ACE2NTD (6xHis) and hRNase A-ACE2NTD (6xHis) fusions are active in cleaving COVID-19 RNA in vitro. The recombinant RNase I (6xHis) and RNase III (6xHis) are active in cleaving RNA and dsRNA in test tube. This study provides a proof-of-concept for construction of fusion protein between human cell receptor and nuclease that may be used to degrade viral nucleic acids in our environment. Graphical Abstract Cartoon illustration part of this work (Human ACE2 N-terminal domain tethered to RNase A and RNA degradation by the fusion enzyme).

Human angiotensin-converting enzyme 2 (ACE2 or ACE-2) is a carboxypeptidase which converts angiotensin I to angiotensin 1-9, and it catalyzes the degradation of angiotensin II to angiotensin 1-7 (reviewed in [1; 2] ), which attenuates inflammation and oxidative stress caused by angiotensin II. ACE2 is a glycoprotein that serves as host cell receptor for the severe acute respiratory syndrome coronavirus (SARS-CoV), human coronavirus NL63/HCoV-NL63, and SARS-CoV-2 [3; 4] . The SARS-CoV-2 is currently causing pandemics and COVID-19 respiratory disease around the globe since its initial outbreak in Wuhan, Hubei Province of China in December 2019 [5] . The first genome sequence was deposited in GenBank/NCBI on Jan. 13, 2020 (Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, GenBank accession number NC_045512). The mortality rate among the elderly (>65) with underlying conditions is high, while the overall fatality rate from positively diagnosed patients in the world stands at ~6.26 % as of April 14, 2020 (120,863 death among over 1.9 million infected when this work was halffinished) [6] . For comparison, the global mortality associated with seasonal influenza epidemics from 2002-2011 (no data in 2009) from World Health Organization was estimated at 0.00058%, or approximately 6 in 10,000 infected individuals in all age groups [7] . Thus, COVID-19 is approximately 10-100 times more lethal in causing human death than seasonal flu, although the mortality rate varies from country to country depending on the medical infrastructure. In majority of COVID-19 positive cases (estimated at ~70% to 80%), the infected individuals show symptoms with fevers and chill, severe muscle pain, cough, symptoms of upper respiratory tract infection and will likely recover after 2-3 weeks. However, the other 20%-30% patients require hospitalization and roughly 5% patients become critically ill and require intensive care and some would eventually develop severe pneumonia (acute respiratory distress syndrome), cardiovascular damage, acute kidney injury, and catastrophic organ failure, possibly owing to acute cytokine storm of massive host immunological reactions [8; 9; 10] . Autoantibodies against immune cells and interferons are also associated with severe COVID-19 disease. The percentage of asymptomatic positive carriers is unknown due to the lack of extensive antibody testing in the general population. The soluble recombinant human ACE2 protein has been shown to drastically reduce virus titer in cell cultures by binding to SARS-CoV-2 virus and preventing reinfection [11] .

The SARS viral spike (S) protein forms a trimer and it's erected active form mediates virus entry into host cells by first binding to the ACE2 receptor through the receptor-binding domain (RBD) in the N-terminal S1 domain (the trimeric Spike protein also binds cellular heparin). Following protease cleavage, fusion of the viral and host membranes through the S2 domain ensued by endocytosis and subsequent release of viral RNA for translation of viral proteins, post-translational processing, viral RNA replication and modification, and virus particle maturation in Golgi apparatus [12; 13; 14; 15] . The life cycle of SARS-CoV-2 is probably very similar to that of SARS-CoV [4; 16] . The receptor binding domain of the S protein (S-RBD) serves as a molecular target for developing virus attachment inhibitors, therapeutic antibodies, and preventive vaccines [17] . The structures of ACE2 receptor with bound S1 domain or fulllength S protein of SARS-CoV-2 have been solved recently at high resolution by Cryo-EM [18; 19] . Recently, COVID-19 virus variants have been isolated in UK, South Africa, Brazil, and US that contain multiple amino acid (aa) mutations in the S protein (e.g. K417N, E484K, N501Y aa substitutions) that may have increased the binding affinity to human ACE2 receptor and enhanced transmission rate [20] . Another host protein, the transmembrane protease, serine 2 (TMPRSS2) is believed to cleave the SARS-CoV-2 spike protein to facilitate cellular attachment and membrane fusion [4; 21] . While cellular proteases furin and cathepsin B/L proteases can also cleave S protein and active the virus for reinfection of other cells. The full-length TMPRSS2 protein is 492-aa long, that can be cleaved into two polypeptides by autocatalysis: N-terminal non-catalytic domain (aa 1-255), and C-terminal catalytic domain (aa 256-492). The Serine protease facilitates the phylogenetically related SARS-CoV virus-cell membrane fusions by proteolytically cleaving and processing the viral spike glycoproteins [22] .

Over-expression of TMPRSS2 in human VeroE6 cells resulted in a cell line VeroE6/TMPRSS2 highly susceptible to SARS-CoV-2 infection and potentially useful for generating high virus titers [23] .

Current strategies to reduce viral transmission among individuals are social distancing (curfew, self-quarantine and/or mandatory shelter in place) to reduce community transmission, chemical treatment and sanitization of public places that may harbor the viral particles, creation of physical barriers (wearing masks, facial shield, protective goggle and gown for health care workers). The SARS-CoV particles on smooth surfaces retained their viability for over 5 days at 22-25°C and relative humidity of 40-50%, however, virus viability was rapidly lost at higher temperatures (>38 o C) and higher relative humidity [24] . The survival of infectious SARS-CoV-2 virus particle in air droplets and solid surfaces is estimated in a few hours to days [25] . Virus particles in the respiratory air droplets (aerosol) from asymptomatic carriers and patients are suspected as transmission route, which resulted in high transmission rate to health care workers in hospitals and other high density social gathering. The degradation and loss of infectivity of the virus particles relies on natural decays of the infectious particles possibly by many environmental factors such as temperature, humidity, pH, protease and RNase and other natural microbial enzymes present under environmental settings. Three vaccines against SARS-CoV-2 Spike (S) protein have been developed by pharmaceutical companies and are being applied to front line medical professionals, senior citizens, essential workers and later to the general population [26; 27; 28; 29; 30; 31; 32] . Phase 1 clinical trial for a single dose intranasal vaccine was initiated in Q4 2020 by Altimmune Inc. and University of Alabama/Birmingham.

Clinical trials have been carried out for treatment of COVID-19 with the nucleotide analog RNA-dependent RNA Polymerase (RdRP) inhibitor RemdesivirÒ, which has been approved by the US Food and Drug Administration to treat COVID-19 patients. Other antiviral drugs include protease inhibitors that inhibit the viral protease (main protease, Mpro) required for the processing of virus polyprotein into functional enzymes (RdRP, RNA helicase, and ribonuclease) for viral genome replication. Other host factors involved in viral replication and maturations have been identified and are being targeted for therapeutic intervention [33] . The overall economic fallout from the SARS-CoV-2 pandemics in the global economy is difficult to quantitate, but the pandemics had negatively impacted on economic activities and GDP, leading to a global recession in 2020.

The E. coli MBP protein expression system utilizes a strong promoter for transcription and a strong ribosome binding site for protein synthesis and the production of target protein is inducible by addition of IPTG (www.neb.com) [34] . Some MBP fusion proteins can be expressed at high level, up to 100 mg per liter (L) of induced cells. In addition, the target protein in fusion with MBP can be exported into bacterial periplasm to avoid toxicity since over-expression of certain enzymes in cytoplasm is toxic to the host. MBP signal peptide directed fusion protein to periplasm (removal of MBP signal peptide). In some cases, MBP fusion with the target protein is active and there is no need to cleave off the MBP tag for enzymatic activity (e.g. MBP-PNGase F (NEB Catalog 2019/20), RNase I f (MBP-RNase I fusion), MBP-Geobacillus intron-encoded reverse transcriptase (Xu, unpublished). The MBP tag can also serve as a chaperon to enhance the fusion protein solubility [34; 35] . The E. coli ribonuclease I (RNase I, periplasmic isoform) belongs to the RNase T2/S-RNase group of endoribonucleases and it had been over-expressed and purified [36] . Bovine RNase A and E. coli RNase I, commercially available in research grade for many years, are widely used to eliminate RNA in preparation of plasmid and genomic DNA for molecular biology applications [37] . E. coli RNase III is an endoribonuclease cleaving double-stranded (ds) duplex RNA that is involved in transcript degradation and accelerated RNA decay and it requires divalent cations for activity [37] . RNase III and its variants can generate small dsRNA (21-23 bp) in Mn 2+ buffer to be used in small RNA-medicated gene transcription regulation [38] . The human ribonuclease A (hRNase A) has eight different secreted variants (isoforms) that have antiviral/antibacterial/antifungal activities, and cytotoxicity against intracellular parasites. hRNase A (pancreatic) encoded by the human rnase1 gene is an endorinuclease cleaving the 3' side of pyrimidine nucleotides of single-stranded and doublestranded RNA [39; 40] . The hRNase A precursor contains 156 aa residues with a signal peptide of 28 residues (128 aa mature protein, Uniprot ID-P07998). The potential of hRNase A as an anti-Covid-19 reagent has not been explored to our knowledge.

The SARS-CoV-2 viral genome is a positive-strand ssRNA of ~30 kb possibly encoding at least 29 viral proteins [41] . In this study, we propose to use ribonucleases (RNases) as an antiviral agent to destroy the viral genome. Our goal is to construct RNase I fusion with human ACE2 receptor protein and to investigate strategies to trigger the destabilization of the viral particles or partially release the RNA genome to become more accessible to RNase degradation.

To achieve this goal, we expressed six proteins in E. coli cells: 1) MBP-ACE2NTD, 2) ACE2 NTD-GFP, 3) RNase I (6xHis), 4) RNase III (6xHis), 5) RNase I-ACE2NTD (6xHis), 6) hRNase A-ACE2NTD. We examined expression conditions and partially purified the fusion protein MBP-ACE2NTD. We optimized expression conditions and strains for RNase I (6xHis) and

RNase III (6xHis). We also constructed and partially purified the fusion enzyme RNase I-ACE2NTD (6xHis) which is active in cleaving RNA in the absence of divalent cations. We also demonstrated that hRNase A-ACE2NTD (6xHis) fusion is active in digestion of Covid-19 RNA fragment and other RNA substrates. We fused ACE2-NTD to GFP that resulted in reduced green fluorescence signal. This construct may be useful to isolate more soluble variants of ACE2NTD by screening mutant libraries. This work serves as a proof of concept for the construction of artificial ribonuclease fused to human ACE2 receptor NTD. The availability of inexpensive recombinant ACE2NTD protein may facilitate the screening of small molecules binding to ACE2 and block SARS virus attachment and entry. 

The full-length ACE2 protein has 805 aa residues (GenBank sequence ID: BAB40370.1). The first 17 aa residues form the signal peptide not required for activity; the extracellular domain is consisted of aa residues 18-740 [42] . Therefore, only the coding sequence for aa residues 12 to 444 is synthesized in two gene blocks (IDT) (the first 11 aa residues were deleted, #12 Val codon was changed to ATG codon for cloning purpose. See the modified protein sequence below). The 

The coding sequence for ACE2NTD was amplified by PCR and inserted into pDasherGFP (NdeI cut, pBR322 backbone, Amp R )(source reference: atum.bio). GFP expression was under the control of T5 promoter and is inducible by addition of IPTG. GFP expressing colonies, GFP and ACE2NTD-GFP protein bands were visualized under long UV light or by a fluorescence imager (Typhoon, GE Lifesciences) at 520 nM (Cy2 channel, 515-535 nm emission).

The RNase I gene (rna) was amplified from E. coli genomic DNA (E. coli strain H709c) and assembled into T7 expression vector pET21b (NdeI and XhoI digested), which produced a Cterminal 6xHis tag. The protein expression level was evaluated in four T7 expression strains: T7 Express (C2566, NEB), T7 Express with LysY and lacI q (C3013, NEB), T7 SHuffle (C3026, E.

coli K strain, NEB) and Nico (lDE3) with reduced histidine-rich background proteins (NEB).

The RNase I precursor contains a signal peptide (amino acid residues 1-23) for export to periplasm. To create RNase I-ACE2NTD fusion, a PCR fragment amplified from ACE2NTD gene block (IDT) was assembled into the XhoI site of pET21b-RNase I, which generated the coding sequence for the fusion RNase I-ACE2NTD (6xHis). The entire gene was sequenced using T7 universal primer(S1248), T7 terminator primer (reverse) (S1271), and internal ACE2 primers. The expression of RNase I-ACE2NTD (6xHis) fusion was evaluated in five T7 expression strains: C2566, C3013, C3026, Nico (lDE3), and BL21 (lDE3). RNase I (6xHis) was partially purified by chromatography through Ni-NTA column (Ni-NTA agarose fast-flow, ThermoFisher). The protein was concentrated by low-speed centrifugation in an Amicon concentrator (10 kDa cut-off) and resuspended in a storage buffer SB (50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 10 mM DTT, 50% glycerol).

The RNase III gene (rnc) was amplified from E. coli genomic DNA (E. coli strain H709c) and assembled into T7 expression vector pET21b (NdeI and XhoI digested), which produced a Cterminal 6xHis tag. The protein expression level was evaluated in three T7 expression strains: T7

Express with LysY and lacI q (C3013), T7 SHuffle (C3026, E. coli K strain) and Nico (lDE3).

RNase III (6xHis) was partially purified by chromatography through Ni-NTA column (Ni-NTA agarose fast-flow, ThermoFisher). The protein was concentrated by low-speed centrifugation in a concentrator and resuspended in a storage buffer SB. RNase III activity was assayed using a 40mer duplex RNA and dsRNA ladder (NEB).

A PCR fragment encoding E. coli RNase I (GenBank Sequence ID: AAB40811.1) was inserted into pMAL-p5x to generate the following construct (the 23-aa signal sequence of RNase I was deleted). The molecular weight of the fusion protein MBP-RNase I is predicted to be ~71.7 kDa (44.5 + 27.2 kDa).

Two versions of fusion were constructed: fusion 1 contains the E. coli MBP signal peptide (aa mM DTT) as RNase I is active in the absence of divalent cations or in the presence of EDTA [37] . Cleavage reactions were quenched by eliminating enzymes with the treatment with Proteinase K (1.6 U, NEB) and the products were analyzed by capillary gel electrophoresis (CE assay). Substrate and cleavage product peaks were analyzed by PeakScan software (ABI/ThermoFisher). 

A schematic diagram of the fusion consisting of an N-terminal MBP and a C-terminal ACE2NTD as well as the cloning sites is shown in Fig. 1A . Total cellular proteins from sonicated cell lysate of IPTG-induced cells (NEB Express, 16 o C overnight) were analyzed by SDS-PAGE (Fig. 1B) . Nine out of 11 clones produced a strong protein band of ~94 kDa, close to the predicted size. Clone #8 contains the correct sequence and was chosen for further analysis.

After 15 min centrifugation of the total lysate in a microcentrifuge, however, most of the MBP-ACE2NTD fusion was found in the pellet (inclusion body) (data not shown). To improve protein folding and solubility, NEB SHuffle E. coli host was tested for protein induction. This strain was engineered to promote disulfide bond formation in the cytoplasm and is deficient in proteases Lon and OmpT. 1 L cell culture was induced with IPTG at 16 o C overnight and the supernatant of cell lysates (the soluble fraction) was loaded onto a 15 ml amylose column. Fig. 1C shows the partially purified fusion protein using an amylose column (~6 mg protein purified from 1 liter LB of IPTG-induced cells including a few contaminating proteins). The ~40 kDa protein is likely to be the host MBP without the signal peptide. To remove this major contaminating protein, an MBP-deficient SHuffle strain will be required. Some fusion protein expressed in NEB SHuffle strain was found in the pellet (Fig. 1C, lane 4) . The protein pellet from NEB Express cells was solubilized. After solubilization and refolding, the fusion protein was partially purified (Fig. 1C, lane 5). The protein yield from solubilized pellet (NEB Express) was approximately 50 mg/L of IPTG-induced cells. The refolded protein can be further purified by incubation with amylose magnetic beads (Fig. 1D) . It was concluded that most of the fusion protein made in NEB Express was found in the pellet (inclusion body). 1 L of IPTG-induced NEB SHuffle cells produced ~6 mg of soluble protein and ~50 mg of insoluble protein in the pellet. The production of MBP-ACE2NTD protein from E. coli cells may have a cost advantage over ACE2 protein produced from human cell cultures. But the ACE2NTD from bacterial source lacks the sugar modifications compared to the human version.

One potential application of MBP-ACE2NTD protein is to serve as a decoy to bind SARS-CoV-2. We examined MBP-ACE2NTD binding to S and RBD protein in vitro by protein pull-down assay. The His-tagged S protein is expected to bind to the Ni magnetic beads. The MBP-ACE2NTD protein was incubated with the S protein pre-bound to the Ni magnetic beads. After extensive washing with high salt buffer, the S protein and potential bound partner were eluted with an elution buffer. In a control experiment, approximately 20% of the S protein can be recovered from the Ni magnetic beads (Suppl. Fig. S1 A. compared lanes 1-input and lane 2recovered). When the S protein was incubated with MBP-ACE2NTD protein, only a very weak band of the binding partner was recovered, indicating poor binding of S protein to MBP-ACE2NTD in vitro under the high salt condition (0.3 M NaCl). In a reversed pull-down assay, the MBP-ACE2NTD bound to the amylose magnetic beads was incubated with S or RBD proteins. After extensive washing, the proteins were eluted with a maltose buffer. Only a weak band of the S protein was detected by anti-6xHis Ab in the Western blot (Suppl. Fig. S1 B) . The RBD protein binds to the binding partner modestly well, as detected by anti-6xHis Ab in the Western blot. In the control experiment, MBP-ACE2NTD was detected by monoclonal anti-ACE2 Ab. The protein binding and pull-down results indicate that the SARS-Cov-2 S protein binds poorly to the MBP-ACE2NTD protein, and the RBD protein binds reasonably well to the fusion in vitro. This result is consistent with published data that the SARS-CoV-2 S protein, unlike SARS-CoV-1 S protein, is a poor binder to the human ACE2 receptor in vitro [18; 19; 42] . It remains to be seen whether some recent SARS-CoV-2 variants (e.g. N501Y, P681H, and DH69/DV70 variants, P.1 variant with K417T/E484K/N501Y amino acid changes in S protein) with higher transmission rate can bind to the ACE2 receptor protein more tightly in vitro [20] (P.1 variant reference: https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-ofconcern-voc-p-1-in-amazonas-brazil/596).

Since ACE2NTD fusion to MBP displayed reduced solubility, it is anticipated that fusion of ACE2NTD to GFP may reduce green fluorescence. ACE2NTD-GFP fusion was constructed by insertion of ACE2NTD coding sequence into the GFP expression vector, creating N-terminal ACE2NTD and C-terminal GFP. GFP-expressing E. coli cells (IPTG-induced) showed strong green fluorescence and formed green colonies under long UV light or at 520 nm light emission (Suppl. Fig. S2 A) 

Express), however, did not show green fluorescence, presumably the ACE2NTD-GFP fusion negatively affected the protein folding and/or expression inside cells. IPTG induced expression of ACE2NTD-GFP fusion showed a weak green fluorescence in NEB SHuffle cells, suggesting improvement of folding of the fusion protein. To further confirm this, the total proteins from IPTG induced cells were analyzed by SDS-PAGE and protein bands were visualized on a fluorescence imager. GFP showed a strong fluorescence signal, but the ACE2NTD-GFP fusion protein showed a weak signal in NEB SHuffle K and B strains (Suppl. Fig. S2 B) (the fluorescence signal presumably resulted from protein refolding after washing three times in Milli-Q water). It was concluded that ACE2NTD likely negatively affected the folding and/or expression of GFP when they were fused together. This fusion system may be used to isolate ACE2NTD variants with improved folding and stronger fluorescence in E. coli from ACE2NTD mutant libraries by simply screening for green colonies among thousands of transformants. It has been shown before that membrane protein fusion to GFP can create fusion problem for GFP with reduced fluorescence [43] . GFP-expressing cell suspensions and lysate (IPTG-induced) showed a yellow/green color under normal light (Suppl. Fig. S2C, D) .

A schematic diagram of the E. coli RNase I and bovine RNase A fusion with MBP is shown in Fig. 2A . The fusion proteins should be exported to the periplasm and the MBP signal peptide being cleaved, but some fusion proteins could exist in the cytoplasm due to the protein overexpression and overwhelming of the export system. Analysis of four cell lysates (total proteins) from NEB Express indicated a strong induced band of 55 to 60 kDa in three out of four samples, in close agreement with the predicted MBP-RNase A fusion (58.3 kDa) (Fig. 2B) . The inserts in plasmid clones (#1, #3, and #4) were sequenced to confirm the correct DNA sequence. After centrifugation, most of the fusion protein was pelleted, and a small fraction was found in the supernatant (Fig. 2C, D) . Attempt to transfer the MBP-RNase A expression clone into NEB SHuffle strain was not successful (few colonies were found in transformation, data not shown), suggesting the fusion protein may be toxic to the host. Bovine RNase A is a single-strand specific enzyme, but at high concentrations it can cleave dsRNA as well [44] . Its over-expression in T7 SHuffle cells appeared to be lethal to the host. A signal peptide may be added to bovine RNase A to be exported to periplasm for its over-expression in E. coli. Due to the low yield of soluble MBP-RNase A (bovine) fusion, the purification was not pursued further.

A PCR fragment encoding the E. coli RNase I was inserted into the pMAL-p5x vector to construct MBP-RNase I fusion. Analysis of 11 cell lysates (total proteins) from IPTG-induced cells (NEB Express) indicated a strong induced band of ~70 kDa in 8 out of 11 samples, in agreement with the predicted MW (71.7 kDa) (Fig. 2C, Suppl. Fig. S3 ). After centrifugation, most of the fusion protein was found in the pellet, and a small fraction remained in the supernatant (Fig. 2C, D) . Attempt to express the fusion in T7 SHuffle cells did not improve the expression level (data not shown). MBP-RNase I fusion appeared to be toxic to T7 SHuffle host since only low-density cells could be obtained in liquid culture at 37 o C. The protein yield of MBP-RNase I was highest in NEB Turbo cells, probably due to the robust cell growth and higher cell weight per liter culture. Fig. 2E shows the partially purified MBP-RNase I fusion in comparison with RNase I f , (RNase I f = MBP-RNase I fusion from NEB as a research grade ribonuclease, M0243S). The enzyme preparation also contained the host MBP. In order to eliminate the MBP, it will be necessary to use an MBP-deficient strain as the expression host. In a ribonuclease activity assay, the partially purified MBP-RNase I is active in digestion of a RNase substrate (fluorescein-labeled 300 nt RNA) (Fig. 2F) .

Previous studies showed that E. coli RNase I does not require divalent cations for nuclease activity, and the other eight ribonucleases from E. coli are only active in the presence of divalent cations [37] . To demonstrate the ribonuclease activity for the partially purified MBP-RNase I, we incubated a low range ssRNA ladder (N0364S, NEB) with the enzyme (3 enzyme dilutions at 2 µg, 0.2 µg, and 0.02 µg) in a high salt buffer supplemented with EDTA, Ni 2+ , Ca 2+ , Mn 2+ , Co 2+ , or Mg 2+ . MBP-RNase I is most active in Ca 2+ , Mn 2+ , and Co 2+ buffers. It is also active in EDTA, Ni 2+ , and Mg 2+ buffers, but with limited digestion at low enzyme input (Suppl. Fig.   S4A ). It is possible that in Ca 2+ , Mn 2+ , and Co 2+ buffers, MBP-RNase I activity is stimulated at the low enzyme concentration. It was concluded that MBP-RNase I fusion can be expressed at moderate level in NEB Turbo and NEB Express cells. A small fraction of the fusion protein was found in the soluble fraction and can be purified by chromatography through amylose column.

The partially purified fusion is active in digestion of RNA in the absence of divalent cations or in the presence of EDTA.

To improve the expression level of RNase I, we also expressed a C-terminal 6xHis-tagged version. E. coli rna gene was inserted into the T7 expression vector pET21b. Its expression level was compared in two T7 expression strains (T7 Express and Nico (lDE3). E. coli RNase I has its own signal peptide to be exported to periplasm. But we detected two versions in over-expression:

RNase I precursor with the signal peptide in cytoplasm and the mature enzyme without the signal peptide. The proteins eluted from C2529 cell lysate contained fewer contaminating proteins than C2566 cells, due to the knock-out mutations of a few Histidine-rich proteins in C2529 (Fig. 3A) .

Two versions of RNase I appeared to be co-purified: a longer cytoplasmic version (cRNase I) with the signal peptide (precursor, 30 kDa), and the shorter version of the periplasmic form (27 kDa). The partially purified enzyme is active in digestion of FAM-labeled COVID-19 RNA (60 mer) in a high salt buffer in the absence of MgCl 2 . We also tested the ribonuclease activity in the presence and absence of divalent cations. RNase I (6xHis) is active in the presence of 10 mM EDTA. The RNase activity is mostly active in buffers with Ca 2+ , Mn 2+ , or Co 2+ at low enzyme concentration (data not shown).

Since the SARS-CoV-2 RNA genome also contains regions of dsRNA (e.g. RNA hairpin stem Fig. 4A shows the expression levels (soluble fractions/supernatant) in the three strains. RNase III (6xHis) was partially purified from a Nickel-NTA agarose column or Ni magnetic beads (Fig. 4B) . It is active in digestion of a 40mer RNA duplex and dsRNA ladder.

The 40mer duplex RNA and dsRNA ladder were digested into smaller fragments as detected in the agarose gel (Fig. 4C) . In a control experiment, the ShortCut RNase III (MBP-RNase III fusion) also digested the RNA substrates and gave rise to similar shortened fragments. It was concluded that RNase III (6xHis) can be expressed in E. coli at high level and it is not toxic to E. coli T7 expression strains. The expression level is comparable in the three strains tested.

Since our constructs of MBP-ACE2NTD and RNases were shown to be folded and soluble, we next sought to generate the fusion protein that can bind S protein and exhibit cleavage activity.

The RNase I-ACE2NTD (6xHis) fusion was expressed in Nico (lDE3). Most of the fusion was found in the inclusion body and only a small fraction was found in the supernatant as detected by anti-6xHis Ab or anti-ACE2 monoclonal Ab in Western blot and SDS-PAGE ( Fig. 5A and B,   Suppl. Fig. S5 ). The RNase I-ACE2NTD (6xHis) fusion pellet was subjected to a refolding procedure and further purified by binding to Ni magnetic beads or Ni spin column (Fig. 5C) . The refolded fusion protein is active in digestion of a 300-nt RNA substrate (Fig. 5D) , similar to the positive controls RNase I (6xHis) and MBP-RNase I. The fusion enzyme purified through Ni magnetic beads and spin column is also active in digestion of COVID-19 RNA (60 mer) (Fig.   5E ). We have not tested the ribonuclease activity on full-length COVID-19 RNA due to local bio-safety regulation on the virus.

A schematic diagram of fusion of hRNase A with ACE2NTD150 (a shorter version of ACE2NTD) is shown in Fig. 6A . A short linker (GSAGSA) is inserted between the fusion partners. hRNase A's native signal peptide was deleted and MBP signal peptide was added. The second clone does not carry any signal peptide (cytoplasmic version). The over-expressed fusions could be detected in IPTG-induced cell lysate (total proteins) as shown in Fig. 6B . The two fusions appeared as closely migrated doublet. It may have something to do with multiple disulfide bonds in hRNase A (8 Cys residues in total, potentially forming 4 disulfide bonds).

With protein loading dye, DTT and heating before SDS-PAGE, some of the disulfide bonds may be reduced to -SH groups, creating a mixture of isoforms with different secondary structures (S-S vs -SH). Another possibility is that export systems are overwhelmed and some of the protein with signal peptide is not secreted. To confirm the identity of the engineered fusion, we perform Western blot using mouse anti-His Ab and anti-ACE2 monoclonal Ab. Fig. 6C shows the soluble fusion proteins detected by the antibodies. There are some minor degradation products from the fusions as detected by the anti-ACE2 Ab. We also tested fusion expression level in Nico (lDE3) and NEB SHuffle T7 (B strain). hRNase A-ACE2NTD150 fusions with or without the MBP signal peptide can be over-expressed in Nico (lDE3) cells (data not shown). However, Most of the hRNase A-ACE2NTD150 fusions (with or without MBP signal peptide) were found in the pellet following centrifugation (data not shown). However, there are still some soluble fusions in the supernatant. The fusion protein hRNase A-ACE2NTD150 (6xHis) (no signal peptide) was partially purified by chromatography through a Ni-NTA agarose column or binding to Ni magnetic beads (Fig. 7A) . The purified fusion proteins were active in cleaving FAM-labeled COVID-19 RNA (60mer) (Fig. 7B) . The substrate RNA completely disappeared after 30 min digestion (at 0.1 µg to 2 µg of the fusion protein). Both RNA substrates and cleavage products were detected after digestion at the lower enzyme concentration (at 1.25 to 10 ng) (Fig. 7B) . Some smaller cleavage products less than 10 nt were not easily detected in the CE assay. To further confirm the ribonuclease activity, we digested a 300-nt RNA and a ssRNA ladder (low MW). Both RNA substrates were degraded by the fusion enzyme as detected on a 6% PAG-urea gel and staining with SYBR green (Fig. 7C) . It was concluded that the fusion enzyme hRNase A-ACE2NTD150 displays ribonuclease activity on both 60mer COVID-19 RNA and other RNA substrates ranging from 50-1000 nt. We have not tested ribonuclease activity on the full-length SARS-CoV-2 viral RNA. The binding affinity to RBD domain of the Spike protein remains to be tested.

The fusion protein expression and purification conditions and activity assays on RNA substrates are summarized in Table 1 .

This work demonstrated that MBP-ACE2NTD, MBP-RNase I, RNase I (6xHis), RNase III (6xHis), RNase I-ACE2NTD (6xHis), hRNase A-ACE2NTD150 can be expressed in E. coli either as soluble protein or refolded protein from inclusion bodies. We tested a number of E. coli expression strains and found that MBP-ACE2NTD expression was partially soluble in T7 SHuffle strain, while RNase I-ACE2NTD (6xHis) fusion was best expressed in Nico (lDE3) or BL21 (lDE3) as refolded protein from inclusion body. RNase I (6xHis) and RNase III (6xHis) expressions were more comparable among the T7 expression strains tested in this work. The over-expression of MBP-RNase A (bovine) hRNase A-ACE2NTD150 fusions, however, is toxic to T7 SHuffle strains. We conclude from this work that different E. coli expression strains need to be tested in order to optimize the expression condition. We only tested low temperature induction at 16 o C to 18 o C and the protein induction level at higher temperatures has not been examined. It is anticipated that protein expression level may be increased due to the higher cell weight at the higher temperature with possible trade-off of lower protein solubility. Large-scale fermentation and low-cost purification will be required for mass production and use of these enzymes as anti-viral agents. Other protein expression system, for example, the yeast expression system could be used to over-express human ACE2 receptor and TMPRSS2. In addition, human ACE2 receptor protein and the serine protease can be expressed and exported to the surface of bacteria and yeast for cell surface display [45] . Homing endonuclease variants have been expressed and selected successfully in yeast surface display; the engineered endonuclease mutants displayed altered specificities with a range of cleavage activities in vitro [46] . The fusion of ACE2NTD to E. coli FimH protein to display on the cell surface did not generate positive results in our preliminary study: the fusion coding sequence can be constructed in DNA level, but no fusion protein was detected by anti-6xHis Ab to detect FimH signal peptide-ACE2NTD-FimH (6xHis) fusion. Presumably the fusion is toxic to the host cell.

The ACE2NTD-GFP fusion may be used as a bio-sensor if more soluble ACE2NTD variants could be isolated. The tight binding of COVID-19 variants to the ACE2NTD-GFP fusion may alter the fluorescence signal intensity.

Future research may be directed towards making full-length recombinant ACE2 receptor from E. coli with co-expression of chaperon proteins to increase solubility (chaperone plasmid set, Takara Bio) [47] . In a previous work, we found co-expression of E. coli GroEL/ES proteins with GmrSD endonuclease greatly improved the solubility of GmrSD [48] . To reduce protein purification cost, expression of RNase I-ACE2 (6xHis) and hRNase A-ACE2 (6xHis) fusions may be carried out using the K. lactis yeast expression system (NEB) to export the recombinant proteins into the culture medium for industrial production of the fusions.

Other SARS-CoV-2 structure proteins and human membrane proteins (e.g. TMPRSS2 serine protease catalytic domain) or furin protease may be added to the recombinant protein mixture to trigger virus binding and viral RNA release (TMPRSS2 and Furin cleave SARS-CoV-2 S protein into S1 and S2 domains). Use of mild detergent, EDTA, and proteases may also destabilize the infectious virus particles and partial release of viral RNA for destruction. More research is urgently needed to validate the enzymatic approach to reduce virus counts and transmission in air droplets and to combat highly transmissible COVID-19 variants.

It is noted that the experiments described in this work were carried out with small fragments of RNA in vitro and that work with real virus is needed to fully evaluate the effectiveness as an anti-viral strategy. We are actively seeking collaborations with academic labs and government institutes.

This work was supported by New England Biolabs, Inc. We thank Andy Gardner, Rich Roberts and Tom Evans for their support and idea development, Andy Gardner for critical comments, Sebastian Gruenberg and Dongxian Yue for research materials, Nono Go for the artistic illustration, and DNA sequencing core lab (NEB) for sequencing and CE analysis.

SYX, AF, THC, EY are employees of New England Biolabs, Inc. New England Biolabs is a manufacturer and vendor of molecular biology reagents, including several enzymes and buffers used in this study. This affiliation does not affect the authors impartiality, adherence to journal standards and policies, or availability of data.

[1] R.R. Gaddam, S. Chambers, and M. Bhatia, ACE and ACE2 in inflammation: a tale of two enzymes. Inflamm Allergy Drug Targets 13 (2014) 224-34. Total cell lysate of pET21b serves as a negative control. C and D. Western blot analysis of the fusion proteins (soluble fraction/supernatant) by anti-6xHis Ab and anti-ACE2 monoclonal Ab.

Partially purified hRNase A-ACE2NTD150 (6xHis) (no signal peptide) by Ni-NTA agarose column chromatography or by binding to Ni magnetic beads. B. RNase activity on FAM-labeled COVID-19 RNA (60mer). Arrows indicate the substrate and cleavage products in the CE assay. C. RNase activity assay on a 300-nt RNA and low MW RNA ladder as analyzed on a 6% PAG-urea gel (stained with SYBR green and visualized on a Typhoon Imager).

The renin-angiotensin system: going beyond the classical paradigms

Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

A novel coronavirus outbreak of global health concern

Global Seasonal Influenza-associated Mortality Collaborator, and G.L.C. Teams*, Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project

What we know so far: COVID-19 current clinical knowledge and research

Hlh Across Speciality Collaboration, COVID-19: consider cytokine storm syndromes and immunosuppression

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells

Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2

Structural characterization of the SARS-coronavirus spike S fusion protein core

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

The spike protein of SARS-CoV--a target for vaccine and therapeutic development

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

A SARS-CoV-2 mRNA Vaccine -Preliminary Report. Reply

Oxford-AstraZeneca COVID-19 vaccine efficacy

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Expression and purification of recombinant proteins by fusion to maltose-binding protein

Solubility-enhancing proteins MBP and NusA play a passive role in the folding of their fusion partners

Overexpression, biophysical characterization, and crystallization of ribonuclease I from Escherichia coli, a broad-specificity enzyme in the RNase T2 family

Bacterial ribonucleases and their roles in RNA metabolism

E38A) generates discrete-sized products from long dsRNA

Degradation of double-stranded RNA by human pancreatic ribonuclease: crucial role of noncatalytic basic amino acid residues

The Ribonuclease A Superfamily in Humans: Canonical RNases as the Buttress of Innate Immunity

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV

New tools for membrane protein research

Fimbriae-assisted bacterial surface display of heterologous peptides

Expanding LAGLIDADG endonuclease scaffold diversity by rapidly surveying evolutionary sequence space

Strategies for the production of recombinant protein in Escherichia coli

Expression and purification of a single-chain Type IV restriction enzyme Eco94GmrSD and determination of its substrate preference

Purification of RNase I (6xHis) and RNase activity assay. A. Purification of RNase I (6xHis) from Nickel-NTA agarose column. Lane 1, RNase I (6xHis) pooled fractions from a nickel column (purified from T7 Express cell extract). Arrows indicate the cytoplasmic RNase I precursor (cRNase I) with the signal peptide (predicted MW 30

RNase I with the signal peptide removed (predicted MW 27.0 kDa). B. RNase activity on a FAM-labeled COVID-19 RNA (60 mer). S = substrate

Positive controls, 50 and 5 U of RNase I f (MBP-RNase I fusion, NEB). RNase I (6xHis) enzyme titration (2 µg to 25 ng protein) was used in the activity assay to digest fixed amount of RNA (16 nM) in NEB buffer 3 at 37 o C for 1 h. Proteinase K (1.6 U) was added to remove RNase I. The final cleavage products were analyzed by capillary electrophoresis (CE) and peaks were visualized by PeakScan

Expression of human ACE2 N-terminal domain (ACE2NTD) in fusion with maltose binding protein and ribonuclease I (RNase I)

and Erbay Yigit New England Biolabs, Inc. 240 County Road

key words: human ACE2 receptor, E. coli ribonuclease I (RNase I), RNase III, RNase I-ACE2NTD fusion, human RNase A-ACE2NTD fusion Supplementary figures

Protein pull-down assays for MBP-ACE2NTD, Spike (S) and RBD protein

His-tagged Spike protein bound to Ni magnetic beads incubated with MBP-ACE2NTD and co-eluted proteins. B. MBP-ACE2NTD bound to amylose magnetic beads incubated with Spike or RBD protein and co-eluted proteins as detected by anti-6xHis and anti-ACE2 Abs

S2. Green fluorescence detection for GFP and ACE2NTD-GFP fusion protein

LysY/lacI q ) cells carrying pBR322 (a negative control) and pBR322-P T5 -lacO-DasherGFP visualized under long UV light. B. E. coli colonies (Amp R transformants) of NEB SHuffle and T7 Express cells expressing GFP or ACE2NTD-GFP fusion visualized under long UV light. GFP expressing colonies show bright green color

Total proteins from cell lysates of NEB SHuffle [ACE2NTD-GFP] (K and B strains) detected by fluorescence imaging at 520 nm (Cy2 channel). Arrows indicate GFP and ACE2NTD-GFP fusion, respectively. The Protein ladder shows no fluorescence and was not detected in the imager. D. Cells suspension of C3013

Express (C2566) cell lysates of ACE2NTD-GFP fusion and GFP. GFP expressing cells and cell lysate show yellow/green color under normal light as visualized by naked eyes

MBP-TMPRSS2 (PRS, lacking the transmembrane domain), MBP-RNase I (RI), MBP-RNase A (RA). A. SDS-PAGE analysis of total proteins in cell lysate. B. SDS-PAGE analysis of soluble proteins (supernatant) in cell lysate

The low range ssRNA ladder (50 to 1000 nt long, NEB) was used as the substrate for RNase activity assay in a high sale buffer (100 mM NaCl

mM Tris-HCl, pH 7.5) supplemented with divalent cations (1 mM) or EDTA (10 mM)

RNase III (6xHis), and RNase I-ACE2NTD (6xHis) fusion. A. Total proteins in cell lysate. B. Soluble proteins in the supernatant after centrifugation in a microcentrifuge (10k rmp/min, 15 min). C and D. 6xHis-tagged proteins detected by anti-6xHis Ab in Western blot